Publications by authors named "J A Aram"
Background: The brain reserve hypothesis posits that larger maximal lifetime brain growth (MLBG) may confer protection against physical disability in multiple sclerosis (MS). Larger MLBG as a proxy for brain reserve, has been associated with reduced progression of physical disability in patients with early MS; however, it is unknown whether this association remains once in the secondary progressive phase of MS (SPMS). Our aim was to assess whether larger MLBG is associated with decreased physical disability progression in SPMS.
View Article and Find Full Text PDFBackground: Disability is associated with alcohol misuse and drug overdose death, however, its association with alcohol-induced death remains understudied.
Objective: To quantify the risk of alcohol-induced death among adults with different types of disabilities in a nationally representative longitudinal sample of US adults.
Methods: Persons with disabilities were identified among participants ages 18 or older in the Mortality Disparities in American Communities (MDAC) study ( = 3,324,000).
Article Synopsis
- Rezafungin, a long-acting echinocandin, is effective for treating candidemia and invasive candidiasis, showing non-inferiority to caspofungin in a Phase 3 study.
- The study included 93 patients on rezafungin and 94 on caspofungin, with similar baseline species distribution across groups and comparable cure rates and mortality outcomes.
- Efficacy was not affected by minimum inhibitory concentration values, and two patients with non-susceptible isolates had successful outcomes with rezafungin treatment.
Background: Scant real-world outcomes data are available among hospitalized patients with candidemia (C) or invasive candidiasis without candidemia (IC) who were treated with an echinocandin and few have assessed if there is an opportunity to accelerate the transition of their care to the outpatient setting. This study described the outcomes associated with echinocandin therapy for C/IC and determined the proportion of patients on an echinocandin at hospital discharge (HD) who were potentially eligible for an earlier HD.
Methods: A retrospective, multicenter observational study was performed using the PINC AI Healthcare Database (January 2016-April 2019) of hospitalized adult patients with C/IC who received ≥3 days of an echinocandin.